Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw.

Thumbigere-Math V, Michalowicz BS, de Jong EP, Griffin TJ, Basi DL, Hughes PJ, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R.

Oral Dis. 2015 Jan;21(1):46-56. doi: 10.1111/odi.12204. Epub 2013 Nov 29.

2.

Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws.

Bagan J, Sáez GT, Tormos MC, Hens E, Terol MJ, Bagan L, Diaz-Fernández JM, Lluch A, Camps C.

Oral Dis. 2014 Jul;20(5):446-52. doi: 10.1111/odi.12150. Epub 2013 Jul 10.

PMID:
23837828
3.

Oxidative stress in bisphosphonate-related osteonecrosis of the jaws.

Bagan J, Sáez GT, Tormos MC, Gavalda-Esteve C, Bagan L, Leopoldo-Rodado M, Calvo J, Camps C.

J Oral Pathol Med. 2014 May;43(5):371-7. doi: 10.1111/jop.12151. Epub 2014 Jan 23.

PMID:
24450511
4.

Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.

Thumbigere-Math V, Michalowicz BS, Hughes PJ, Basi DL, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R.

J Oral Maxillofac Surg. 2016 Apr;74(4):738-46. doi: 10.1016/j.joms.2015.09.028. Epub 2015 Oct 3.

5.

Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw.

Polidoro S, Broccoletti R, Campanella G, Di Gaetano C, Menegatti E, Scoletta M, Lerda E, Matullo G, Vineis P, Berardi D, Scully C, Arduino PG.

Mutat Res. 2013 Oct 9;757(2):104-13. doi: 10.1016/j.mrgentox.2013.07.003. Epub 2013 Jul 24.

PMID:
23892139
6.

Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.

Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F.

Anticancer Res. 2013 Sep;33(9):3917-24.

PMID:
24023329
7.

Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates.

Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR.

Bone. 2013 Nov;57(1):201-5. doi: 10.1016/j.bone.2013.08.005. Epub 2013 Aug 14.

8.

Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.

Matsuo A, Hamada H, Kaise H, Chikazu D, Yamada K, Kohno N.

Acta Odontol Scand. 2014 Nov;72(8):656-63. doi: 10.3109/00016357.2014.887772. Epub 2014 Feb 12.

PMID:
24521290
9.

Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link?

De Ceulaer J, Tacconelli E, Vandecasteele SJ.

Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1873-80. doi: 10.1007/s10096-014-2160-5. Epub 2014 Jun 1. Review.

PMID:
24880820
10.

Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation.

Then C, Hörauf N, Otto S, Pautke C, von Tresckow E, Röhnisch T, Baumann P, Schmidmaier R, Bumeder I, Oduncu FS.

Onkologie. 2012;35(11):658-64. doi: 10.1159/000343950. Epub 2012 Oct 22.

PMID:
23147542
11.

Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics.

Kim JH, Ko YJ, Kim JY, Oh Y, Hwang J, Han S, Kim S, Lee JH, Han DH.

PLoS One. 2015 Feb 10;10(2):e0118084. doi: 10.1371/journal.pone.0118084. eCollection 2015.

12.

Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw.

Thumbigere-Math V, Michalowicz BS, Hodges JS, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R.

J Periodontol. 2014 Feb;85(2):226-33. doi: 10.1902/jop.2013.130017. Epub 2013 Jun 20.

13.

Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.

O'Ryan FS, Lo JC.

J Oral Maxillofac Surg. 2012 Aug;70(8):1844-53. doi: 10.1016/j.joms.2011.08.033. Epub 2012 May 16.

PMID:
22595135
14.

Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?

Petcu EB, Ivanovski S, Wright RG, Slevin M, Miroiu RI, Brinzaniuc K.

Diagn Pathol. 2012 Jul 6;7:78. doi: 10.1186/1746-1596-7-78.

15.

Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases.

Hoefert S, Schmitz I, Weichert F, Gaspar M, Eufinger H.

Clin Oral Investig. 2015 Mar;19(2):497-508. doi: 10.1007/s00784-014-1273-7. Epub 2014 Jun 24.

PMID:
24957986
16.

IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.

Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, Le AD.

Clin Cancer Res. 2013 Jun 15;19(12):3176-88. doi: 10.1158/1078-0432.CCR-13-0042. Epub 2013 Apr 24.

17.

Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC.

J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.

PMID:
19531404
18.

Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB.

Cochrane Database Syst Rev. 2016 Feb 26;2:CD008455. doi: 10.1002/14651858.CD008455.pub2. Review.

PMID:
26919630
19.

Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw.

de Boissieu P, Trenque T.

Expert Opin Drug Saf. 2015 Jul;14(7):1015-21. doi: 10.1517/14740338.2015.1044968. Epub 2015 May 5.

PMID:
25943856
20.

Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.

Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI.

Oncologist. 2012;17(2):279-87. doi: 10.1634/theoncologist.2011-0202. Epub 2012 Jan 20.

Supplemental Content

Support Center